Key Highlights

  • BioVie (NASDAQ:BIVI) traded at USD 1.40 intraday on November 4, 2026, down 19.08%, on Volume of 419.09K shares and an intraday market Capitalization of about USD 11.94 million.
  • The company release dated November 4, 2026 priced 2,962,500 shares at USD 1.60, with matching warrants at USD 1.70, for about USD 4.74 million of gross proceeds.
  • The offering price sits below the calculated prior close of USD 1.73, and the warrants add a second layer of possible future share issuance for existing holders to absorb.
  • BioVie is a clinical-stage company with no approved product, so financing terms and cash runway, not revenue, are the main drivers of how the market reads each new raise.

What Moved BioVie During Trading (down USD 0.33, 19.08%)

Shares of BioVie (NASDAQ:BIVI) were quoted at USD 1.40 during regular trading on November 4, 2026, a decline of 19.08%. Working backward, the implied prior close was USD 1.73 (calculated as USD 1.40 divided by 0.8092), so the intraday drop equals USD 0.33 per share. Volume of 419.09K shares ran at about 0.29 times the average. The company release dated November 4, 2026 announced the pricing of a registered direct offering and a concurrent private placement. It is the only company announcement dated November 2 to November 4, 2026 identified.

How the Offering Is Structured

According to the company release, a single healthcare-focused institutional investor agreed to buy 2,962,500 shares of common stock, or common stock equivalents in lieu of shares, at USD 1.60 each. The price is described as at-the-market under Nasdaq rules. In a concurrent private placement, the investor also receives unregistered warrants for up to 2,962,500 shares at an exercise price of USD 1.70. The warrants become exercisable six months after issuance and expire five and a half years after issuance. Gross proceeds are about USD 4.74 million before Placement agent commissions and expenses. Closing is expected on or about November 5, 2026, subject to customary conditions, and proceeds are earmarked for Working Capital and general corporate purposes.

Dilution, Cash Needs and Small-Cap Risk

A registered direct offering creates new shares and sells them at a price that is usually set close to or below the last trade, so each existing share represents a smaller slice of the company. Against the intraday market capitalization of about USD 11.94 million, the USD 4.74 million raise is roughly 40% of that value (simple arithmetic on two published numbers). The warrants could add 2,962,500 more shares if exercised, although a USD 1.70 strike sits above the current quote, so they have no immediate value to the holder. For a company this small, a limited number of trades can move the price, spreads can be wide and quoted moves can reverse. Nothing here implies the decline will continue.

Where Things Stand

BioVie (NASDAQ:BIVI) is down 19.08% intraday because the company priced a USD 4.74 million registered direct offering on November 4, 2026, selling new shares at USD 1.60 and attaching warrants at USD 1.70. The deal extends cash but expands the share count, and the quoted price sits below the calculated prior close of USD 1.73. Investors will watch the closing expected on or about November 5, 2026 and how the proceeds are deployed.